Seres reports preliminary Q4 VOWST net sales of $10.4M; FDA Fast Track for SER-155

Seres Therapeutics, Inc.

2023-FY EPS reported -$0.89 revenue$126,325,000

VOWST Q4 2023 net sales approx $10.4M (unaudited); total 2023 net sales since June launch approx $19.6M.
2,833 patient enrollment forms received and 2,015 new patient starts since launch through year-end 2023.
SER-155 received FDA Fast Track Designation; Phase 1b Cohort 2 data readout expected in Q3 2024.
Preliminary cash, cash equivalents, and investments of approx $128M as of Dec 31, 2023.
Company expects cash plus expected $45M Tranche B from Oaktree to support operations into Q4 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Seres Therapeutics, Inc. reported the fourth quarter of 2023 results: revenue net sales of VOWST of approximately $10.4 million (unaudited).

Period: the fourth quarter of 2023
Revenue: net sales of VOWST of approximately $10.4 million (unaudited)
Result: preliminary results

Exact text from the filing

On January 9, 2024, Seres Therapeutics, Inc. (the “Company”) issued a press release in which the Company announced, among other things, that based on preliminary financial results, the Company had net sales of VOWST of approximately $10.4 million (unaudited) in the fourth quarter of 2023, and preliminary cash, cash equivalents and investments of approximately $128 million (unaudited) as of December 31, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Seres Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-005614

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.